Treatment of Pulmonary Hypertension

This invention relates to the use of certain cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

Saved in:
Bibliographic Details
Main Authors LUKAS TIMOTHY MICHAEL, MACHIN IAN, BUTROUS GHAZWAN SALEEM
Format Patent
LanguageEnglish
Published 08.08.2013
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to the use of certain cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.
Bibliography:Application Number: US201313826769